Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation

European Neuropsychopharmacology

Volumn 24, Issue 1, 2014, Pages 148-159

  Jensen, Jesper Bornø ^a   du Jardin, Kristian Gaarn ^a   Song, Dekun ^a   Budac, David ^a   Smagin, Gennady ^a   Sanchez, Connie ^a   Pehrson, Alan Lars ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

5 HT depletion; Cognitive impairment; Lu AA21004; Major depressive disorder; Memory; Vortioxetine

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; DULOXETINE; ESCITALOPRAM; FENCLONINE METHYL ESTER; SEROTONIN; SEROTONIN RECEPTOR; VORTIOXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG DOSE; EX VIVO STUDY; FEMALE; HIPPOCAMPUS; LOCOMOTION; MEMORY DISORDER; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; WORKING MEMORY;

5-HT DEPLETION; COGNITIVE IMPAIRMENT; LU AA21004; MAJOR DEPRESSIVE DISORDER; MEMORY; VORTIOXETINE;

5-HYDROXYTRYPTOPHAN; ANIMALS; CARBIDOPA; CITALOPRAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; HIPPOCAMPUS; MAZE LEARNING; MEMORY DISORDERS; PHENYLALANINE; PIPERAZINES; PROTEIN BINDING; RATS; RATS, LONG-EVANS; RECOGNITION (PSYCHOLOGY); SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SULFIDES; THIOPHENES;

EID: 84892481016     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.10.011     Document Type: Article

References (52)

1. Airaksinen E., Larsson M., Lundberg I., Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol. Med. 2004, 34:83-91.
2. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implications for functional neuropathology. Br. J. Psychiatry 2001, 178:200-206.
3. Bang-Andersen B., Ruhland T., Jorgensen M., Smith G., Frederiksen K., Jensen K.G., Zhong H., Nielsen S.M., Hogg S., Mørk A., Stensbol T.B. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 2011, 54:3206-3221.
4. Benkelfat C., Ellenbogen M.A., Dean P., Palmour R.M., Young S.N. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch. Gen. Psychiatry 1994, 51:687-697.
5. Bertrand F., Lehmann O., Galani R., Lazarus C., Jeltsch H., Cassel J.C. Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats. Pharmacol. Biochem. Behav. 2001, 68(4):647-660.
6. Bolles R.C., Duncan P.M., Grossen N.E., Matter C.F. Relationship between activity level and body temperature in the rat. Psychol. Rep. 1968, 23:991-994.
7. Booij L., Van der Does A.J., Haffmans P.M., Reidel W.J., Fekkes D., Blom M.J. The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. J. Psychopharmacol. 2005, 19:267-275.
8. Capone F., Venerosi A., Puopolo M., Alleva E., Cirulli F. Behavioral responses of 129/Sv, C57BL/6J, and DBA/2J mice to a non-predator aversive olfactory stimulus. Acta Neurobiol. Exp. Wars 2005, 65:29-38.
9. Cassano G.B., Puca F., Scapicchio P.L., Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J. Clin. Psychiatry 2002, 63:396-402.
10. Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress. Anx. 2005, 21:78-89.
11. Dailly E., Chenu F., Petit-Demouliere B., Bourin M. Specificity and efficacy of noradrenaline, serotonin depletion in discrete brain areas of Swiss mice by neurotoxins. J. Neurosci. Methods 2006, 150:111-115.
12. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 1990, 47:411-418.
13. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., Charney D.S. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry 1994, 51(11):865-874.
14. du Jardin K.G., Jensen J.B., Sanchez C. and Pehrson A.L., Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism, Eur. Neuropsychopharmacol. in press, 〈〉. http://dx.doi.org/10.1016/j.euroneuro.2013.07.001.
15. Dunkin J.J., Leuchter A.F., Cook I.A., Kasl-Godley J.E., Abrams M., Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J. Affect. Disord. 2000, 60:13-23.
16. Ferguson J.M., Wesnes K.A., Schwartz G.E. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int. Clin. Psychopharmacol. 2003, 18:9-14.
17. Gobbi M., Frittoli E., Mennini T., Garattini S. Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. Naunyn Schmiedeberg's Arch. Pharmacol. 1992, 345:1-6.
18. Herrera-Guzman I., Gudayol-Ferre E., Herrera-Guzman D., Guardia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J. Psychiatric Res. 2009, 43:855-863.
19. Herrera-Guzman I., Herrera-Abarca J.E., Gudayol-Ferre E., Herrera-Guzman D., Gomez-Carbajal L., Pena-Olvira M., Villuendas-Gonzalez E., Joan G.O. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010, 177:323-329.
20. Herrera-Guzman I., Gudayol-Ferre E., Herrera-Abarca J.E., Herrera-Guzman D., Montelongo-Pedraza P., Blazquez F.P., Pero-Cebollero M., Guardia-Olmos J. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J, Affect, Disord. 2010, 123:341-350.
21. Hori S.E., Powell K.J., Robertson G.S. Darbepoetin (Aranesp) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults. Neuroscience 2007, 144:1-7.
22. Horiguchi M., Meltzer H.Y. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology 2012, 221:205-215.
23. Hritcu L., Clicinschi M., Nabeshima T. Brain serotonin depletion impaits short-term memory, but not long term memory in rats. Physiol. Behav. 2007, 91:652-657.
24. Jakala P., Sirvio J., Riekkinen P., Reikkinen P.J. Effects of p-cholorophenylalanine and methysergide on the performance of a working memory task. Pharmacol. Biochem. Behav. 1993, 44:411-418.
25. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006, 145:39-48.
26. Jans L.A., Korte-Bouws G.A., Korte S.M., Blokland A. The effects of acute tryptophan depletion on affective behavior and cognition in Brown Norway and Sprague Dawley rats. J. Psychopharmacol. 2010, 24:605-614.
27. Kampf-Sherf O., Zlotogorski Z., Gilboa A., Speedie L., Lereya J., Rosca P., Shavit Y. Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J. Affect. Disord. 2004, 82:453-459.
28. Kaneda Y. Verbal working memory and functional outcome in patients with unipolar major depressive disorder. World J. Biol. Psychiatry 2009, 10:591-594.
29. Katona C., Hansen T., Olsen C.K. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 2012, 27:215-223.
30. Kuny S., Stassen H.H. Cognitive performance in patients recovering from depression. Psychopathology 1995, 28:190-207.
31. Lee R.S., Hermens D.F., Porter M.A., Redoblado-Hodge M.A. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J. Affect. Disord. 2012, 140:113-124.
32. Levkovitz Y., Caftori R., Avital A., Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res. Bull. 2002, 58:345-350.
33. Lin M.T., Chern Y.F., Chern S.I. The effects of brain monoamine depletion on p-chlorohenyl-alanine-induced hypothermia. Experientia 1978, 34:1595-1596.
34. Lieben C.K., Steinbusch H.W., Blokland A. 5,7-DHT lesion of the dorsal raphe nuclei impairs object recognition but not affective behavior andcorticosterone response to stressor in the rat. Behav. Brain Res. 2006, 168:197-207.
35. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N., Okado N. Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997, 230:13-16.
36. McFarland D.J. Effects of scopolamine, d-amphetamine, and apomorphine on alternation and position biases. Pharmacol. Biochem. Behav. 1989, 32(3):723-726.
37. Mørk A., Montezinho L.P., Miller S., Trippodi-Murphy C., Plath N., Li Y., Gulinello M., Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol. Biochem. Behav. 2013, 105:41-50. http://dx.doi.org/10.1016/j.pbb.2013.01.019.
38. Mørk A., Pehrson A., Brennum L.T., Nielsen S.M., Zhong H., Lassen A.B., Miller S., Westrich L., Boyle N.J., Sanchez C., Fischer C.W., Liebenberg N., Wegener G., Bundgaard C., Hogg S., Bang-Andersen B., Stensbol T.B. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharm. Exp. Ther. 2012, 340:666-675.
39. Nebes R.D., Pollock B.G., Houck P.R., Butters M.A., Mulsant B.H., Zmuda M.D., Reynolds C.F. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J. Psychiatric Res. 2003, 37:99-108.
40. Pehrson A.L., Cremers T., Bétry C., van der Hart M.G.C., Jørgensen L., Madsen M., Haddjeri.N., Ebert B., Sanchez C. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-a rat microdialysis and electrophysiology study. Eur. Neuropsychopharmacol. 2013, 23(2):133-145.
41. Pehrson A.L. and Sanchez C., Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction, CNS Spectrums in press, http://dx.doi.org/10.1017/S1092852913000540.
42. Petkov V.D., Belcheva S., Konstantinova E., Kehayov R. Participation of different 5-HT receptors in the memory process in rats and its modulation by the serotonin depletor p-chlorophenylalanine. Acta Neurobiol. Exp. 1995, 55:243-252.
43. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego. 4th ed.
44. Prinssen E.P., Assie M.B., Koek W., Kleven M.S. Depletion of 5-HT disrupts prepulse inhibition in rats: dependence on the magnitude of depletion, and reversal by a 5-HT precursor. Neuropsychopharmacology 2002, 26:340-347.
45. Reidel W.J., Klaassen T., Deutz N.E., van Someren A., van Praag H.M. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl) 1999, 141:362-369.
46. Refinetti R. Relationship between the daily rhythms of locomotor activity and body temperature in eight mammalian species. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1999, 277:R1493-R1500.
47. Ross S.M. Pierce's criterion for the elimination of suspect experimental data. J. Eng. Technol. 2003, 20:38-41.
48. Rutten K., Lieben C., Smits L., Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 2007, 192:275-282.
49. Satinoff E., Kent S., Li H., Megirian D., Tomkowiak J.M. Circadian rhythms of body temperature and drinking and responses to thermal challenge in rats after PCPA. Pharmacol. Biochem. Behav. 1991, 38:253-257.
50. Sobczak S., Reidel W.J., Booij L., Rot Aan Het, Deutz M., Honig, A.N.E. Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar patients and matched healthy control volunteers. Psychol. Med. 2002, 32:503-515.
51. Staubli U., Xu F.B. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory and LTP induction in the freely moving rat. J. Neurosci. 1995, 15:2445-2452.
52. Westrich L., Pehrson A., Zhong H., Nielsen S.M., Fredericksen K., Stensbøl T.B., Boyle N., Hentzer M., Sanchez C. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int. J. Psychiatry Clin. Pract. 2012, 5(Suppl. 1):47.